Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

VIP, AMAZING NEUROPEPTIDE———

Role of vasoactive intestinal peptide in osteoarthritis ——————————

Vasoactive intestinal peptide (VIP) plays important roles in many biological functions, such as, stimulation of contractility in the heart, vasodilation, promoting neuroendocrine-immune communication, lowering arterial blood pressure, and anti-inflammatory and immune-modulatory activity. Osteoarthritis (OA) is a chronic and degenerative bone disease, which is one of the most common causes of disability and most common in both sexes as people become older. Interestingly VIP can prevent chronic cartilage damage and joint remodeling......A number of studies indicated that up-regulation of VIP can counteract the action of pro-inflammatory stimuli and alleviate the pain in OA. More clinical investigations are necessary to determine the biology of VIP and its therapeutic potential in OA that might represent the future standards of care for OA.

https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0280-1

The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.

https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html